Skip to content

Flucelvax Pregnancy Registry

Flucelvax Pregnancy Registry: an Observational Study on the Safety of Flucelvax Exposure in Pregnant Women and Their Offspring

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02258178
Enrollment
0
Registered
2014-10-07
Start date
2014-09-30
Completion date
2020-06-30
Last updated
2017-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnant Women, Influenza

Brief summary

The goal of the registry is to develop a better understanding of the safety of Flucelvax in women and their offspring who were exposed to the vaccine during pregnancy

Interventions

BIOLOGICALFlucelvax (cTIV)

vaccine exposure in routine care (no vaccination per protocol)

Sponsors

Seqirus
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnancy women pregnant women aged 18 years or older within the US who were immunized with the Flucelvax vaccine at any time during pregnancy.The registry will allow eligible pregnant women to selfenroll and also allow HCPs to report de-identified data on pregnancy exposures and outcomes. * Sufficient evidence to confirm that Flucelvax exposure occurred during pregnancy * Sufficient information to determine whether the pregnancy is prospectively or retrospectively registered (ie, whether the outcome of pregnancy was known at the time of first contact with the registry) * Date the pregnancy exposure is registered * Full reporter (ie, HCP) contact information to allow for follow-up (name, address,etc) The primary population for analysis will include prospectively enrolled pregnancies exposed to Flucelvax that are not lost to follow-up (ie, with outcome information that meet the minimum criteria for evaluation)

Exclusion criteria

* Invalid registry reports and pregnancies deemed lost to follow-up will be excluded from the primary analysis. Retrospective reports will not be included, although retrospective cases with MCMs will be reviewed and reported separately.

Design outcomes

Primary

MeasureTime frame
major congenital malformationFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
preterm birthFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
low birth weightFrom time of enrollment during pregnancy to time of delivery or pregnancy termination

Other

MeasureTime frame
spontaneous abortionFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
molar pregnancyFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
ectopic pregnancyFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
Live birthFrom time of enrollment during pregnancy to time of delivery or pregnancy termination
stillbirthFrom time of enrollment during pregnancy to time of delivery or pregnancy termination

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026